|
|
|
Location: Home -
Products - Active Pharma Ingredients(API) - Peptide APIs
|
Degarelix acetate(FE-200486)
Catalogue No. : |
C13549 |
Product Name: |
Degarelix acetate(FE-200486) |
Synonym: |
Degarelix acetate; FE-200486;FE200486;Firmagon;N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-4-[2,6-dioxohexahydropyrimidin-4(S)-ylcarboxamido]-L-phenylalanyl-4-ureido-D-phenylalanyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide acetate |
Chemical Name: |
Sequence: Ac-D-Nal-D-Cpa-D-Pal-Ser-Aph(2,6-dioxohexahydropyrimidin-4(S)-ylcarboxamido)-D-Aph-Leu-Lys(N6-isopropyl)-Pro-Ala-NH2 acetate salt |
CAS No. : |
214766-78-6 |
Structure : |
|
Molecular Formula: |
C82H103CLN18O16 |
Molecular Weight: |
1632.28 |
Appearance: |
White to off-white powder |
Purity: |
Purity(HPLC)>98% |
Usage: |
Degarelix Acetate is an LHRH (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Degarelix reversibly and dose-dependently suppresses gonadotropin and sex steroid levels by inhibiting the binding of endogenous LHRH to its receptors.Degarelix showed to be at least as effective as leuprolide in sustaining levels of testosterone that are equivalent to or lower than that seen with castration. Degarelix or degarelix acetate(Firmagon) is a hormonal therapy used in the treatment of prostate cancer. During development it was known as FE200486. |
|
Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|